FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138004978> ?p ?o ?g. }

• W3138004978 endingPage "1659" @default.
• W3138004978 startingPage "1650" @default.
• W3138004978 abstract "CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but relapse rates are high. The role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy to improve long-term outcomes in CAYAs has not been examined.We conducted a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL. Response and long-term clinical outcomes were assessed in relation to disease and treatment variables.Fifty CAYAs with B-ALL were treated (median age, 13.5 years; range, 4.3-30.4). Thirty-one (62.0%) patients achieved a complete remission (CR), 28 (90.3%) of whom were minimal residual disease-negative by flow cytometry. Utilization of fludarabine/cyclophosphamide-based lymphodepletion was associated with improved CR rates (29/42, 69%) compared with non-fludarabine/cyclophosphamide-based lymphodepletion (2/8, 25%; P = .041). With median follow-up of 4.8 years, median overall survival was 10.5 months (95% CI, 6.3 to 29.2 months). Twenty-one of 28 (75.0%) patients achieving a minimal residual disease-negative CR proceeded to alloHSCT. For those proceeding to alloHSCT, median overall survival was 70.2 months (95% CI, 10.4 months to not estimable). The cumulative incidence of relapse after alloHSCT was 9.5% (95% CI, 1.5 to 26.8) at 24 months; 5-year EFS following alloHSCT was 61.9% (95% CI, 38.1 to 78.8).We provide the longest follow-up in CAYAs with B-ALL after CD19-CAR T-cell therapy reported to date and demonstrate that sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT can mediate durable disease control in a sizable fraction of CAYAs with relapsed or refractory B-ALL (ClinicalTrials.gov identifier: NCT01593696)." @default.
• W3138004978 created "2021-03-29" @default.
• W3138004978 creator A5014636271 @default.
• W3138004978 creator A5017207916 @default.
• W3138004978 creator A5030044268 @default.
• W3138004978 creator A5035242151 @default.
• W3138004978 creator A5044239219 @default.
• W3138004978 creator A5047300808 @default.
• W3138004978 creator A5057326464 @default.
• W3138004978 creator A5065611220 @default.
• W3138004978 creator A5065696086 @default.
• W3138004978 creator A5071031431 @default.
• W3138004978 creator A5072166479 @default.
• W3138004978 creator A5074922008 @default.
• W3138004978 creator A5076065961 @default.
• W3138004978 creator A5087779758 @default.
• W3138004978 date "2021-05-20" @default.
• W3138004978 modified "2023-10-14" @default.
• W3138004978 title "Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL" @default.
• W3138004978 cites W1619537825 @default.
• W3138004978 cites W1973617793 @default.
• W3138004978 cites W2051549641 @default.
• W3138004978 cites W2054326876 @default.
• W3138004978 cites W2079459221 @default.
• W3138004978 cites W2082708772 @default.
• W3138004978 cites W2099570622 @default.
• W3138004978 cites W2105400883 @default.
• W3138004978 cites W2129702476 @default.
• W3138004978 cites W2342423058 @default.
• W3138004978 cites W2529226476 @default.
• W3138004978 cites W2591709377 @default.
• W3138004978 cites W2606654718 @default.
• W3138004978 cites W2610154296 @default.
• W3138004978 cites W2753358840 @default.
• W3138004978 cites W2760653955 @default.
• W3138004978 cites W2787301955 @default.
• W3138004978 cites W2787621143 @default.
• W3138004978 cites W2793770585 @default.
• W3138004978 cites W2891253541 @default.
• W3138004978 cites W2891679914 @default.
• W3138004978 cites W2904113934 @default.
• W3138004978 cites W2905654445 @default.
• W3138004978 cites W2911504656 @default.
• W3138004978 cites W2917127842 @default.
• W3138004978 cites W2980400657 @default.
• W3138004978 cites W2980542859 @default.
• W3138004978 cites W2985081230 @default.
• W3138004978 cites W2990595177 @default.
• W3138004978 cites W3000703533 @default.
• W3138004978 cites W4242997939 @default.
• W3138004978 cites W4293241248 @default.
• W3138004978 doi "https://doi.org/10.1200/jco.20.02262" @default.
• W3138004978 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8274806" @default.
• W3138004978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33764809" @default.
• W3138004978 hasPublicationYear "2021" @default.
• W3138004978 type Work @default.
• W3138004978 sameAs 3138004978 @default.
• W3138004978 citedByCount "144" @default.
• W3138004978 countsByYear W31380049782021 @default.
• W3138004978 countsByYear W31380049782022 @default.
• W3138004978 countsByYear W31380049782023 @default.
• W3138004978 crossrefType "journal-article" @default.
• W3138004978 hasAuthorship W3138004978A5014636271 @default.
• W3138004978 hasAuthorship W3138004978A5017207916 @default.
• W3138004978 hasAuthorship W3138004978A5030044268 @default.
• W3138004978 hasAuthorship W3138004978A5035242151 @default.
• W3138004978 hasAuthorship W3138004978A5044239219 @default.
• W3138004978 hasAuthorship W3138004978A5047300808 @default.
• W3138004978 hasAuthorship W3138004978A5057326464 @default.
• W3138004978 hasAuthorship W3138004978A5065611220 @default.
• W3138004978 hasAuthorship W3138004978A5065696086 @default.
• W3138004978 hasAuthorship W3138004978A5071031431 @default.
• W3138004978 hasAuthorship W3138004978A5072166479 @default.
• W3138004978 hasAuthorship W3138004978A5074922008 @default.
• W3138004978 hasAuthorship W3138004978A5076065961 @default.
• W3138004978 hasAuthorship W3138004978A5087779758 @default.
• W3138004978 hasBestOaLocation W31380049782 @default.
• W3138004978 hasConcept C121332964 @default.
• W3138004978 hasConcept C126322002 @default.
• W3138004978 hasConcept C142424586 @default.
• W3138004978 hasConcept C203014093 @default.
• W3138004978 hasConcept C2776694085 @default.
• W3138004978 hasConcept C2776755627 @default.
• W3138004978 hasConcept C2777408962 @default.
• W3138004978 hasConcept C2778461978 @default.
• W3138004978 hasConcept C2779263901 @default.
• W3138004978 hasConcept C2779823535 @default.
• W3138004978 hasConcept C2911091166 @default.
• W3138004978 hasConcept C71924100 @default.
• W3138004978 hasConcept C72563966 @default.
• W3138004978 hasConcept C87355193 @default.
• W3138004978 hasConcept C88879693 @default.
• W3138004978 hasConcept C90924648 @default.
• W3138004978 hasConceptScore W3138004978C121332964 @default.
• W3138004978 hasConceptScore W3138004978C126322002 @default.
• W3138004978 hasConceptScore W3138004978C142424586 @default.
• W3138004978 hasConceptScore W3138004978C203014093 @default.
• W3138004978 hasConceptScore W3138004978C2776694085 @default.

• next